2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2640 Cost-effectiveness of bispecific antibodies vs CAR T in relapsed refractory follicular lymphoma

Swetha Thiruvengadam, MD, Sitong Chen, MPH2, Stacy Pak, PharmD3, F. Lennie Wong, PhD4, Nikhil Thiruvengadam5
1 City of Hope National Medical Center, Duarte, United States
2 City of Hope National Medical Center, Duarte, United States
3 City of Hope National Medical Center, Duarte, United States
4 City of Hope National Medical Center, Duarte, United States
5 Loma Linda University, Loma Linda, United States

Background

 

T-cell-engaging therapies, including chimeric antigen receptor therapy (CAR T) and bispecific antibodies (BsAbs), have revolutionized the treatment of relapsed refractory follicular lymphoma (R/R FL), with both treatments approved after 2 prior lines of treatment. However, both are associated with high costs and risk of immune-related adverse events. Both strategies rely on recruiting patients’ T-cells against specific tumor antigens, but the ideal sequencing of these therapeutics, given their different administration modalities, costs, and toxicity profiles, remains unclear. We evaluated the cost-effectiveness of BsAb vs. CAR T for R/R FL after 2 prior lines of therapy to help inform providers, payors, and societies.

 

Methods

 

We modeled a hypothetical cohort of US adults (mean age, 62 years) with R/R FL (after 2 prior lines of treatment) by developing a Markov model observing the cohort each month over their remaining lifetimes. The cost-effectiveness of the following two strategies was compared: 1) BsAbs-first followed by CAR T for patients refractory to BsAb or who relapsed after completing BsAb therapy; 2) CAR T first followed by BsAb for refractory or relapsed patients. A range of plausible long-term outcomes were considered. A patient with FL in remission after treatment could progress, relapse, develop alternative toxicities, or die. Progression rates and overall survival were extracted from published phase II pivotal trials, ZUMA 5 for CAR T and GO29781 for BsAbs.   Individual patient-level data were re-created from the Kaplan-Meier curves from these pivotal trials for overall survival and progression-free survival and fit to various parametric curves, which were used to determine progression rates. Costs for inpatient and outpatient care were obtained from public data sources, while drug costs were obtained from Micromedex. Utility values were obtained from the literature. We used a modified societal perspective that included all treatment-related costs and a lifetime time horizon. A discounting rate of 3% was assumed. Outcome measures were reported as incremental cost-effectiveness ratios (ICERs). A strategy with an ICER < willingness-to-pay (WTP) of $150,000/quality-adjusted life-year (QALY) was considered cost-effective.

 

 

Results

 

Despite a CAR T-first strategy being more effective (0.056 incremental QALYs) compared to the BsABs-first strategy, the CAR T-first strategy for RRFL was more costly (total cost of $43,016) and thus was not cost-effective (ICER $768,143/QALY). A tornado analysis demonstrated that the model was primarily sensitive to the cost of BsAbs and the cost of CAR T. One-way sensitivity analysis demonstrated that the BsAbs-first strategy is cost-effective up to a monthly cost of $41,400 for BsAbs therapy. Two-way sensitivity analyses of the cost of CAR T and total cost of BsAbs therapy demonstrated that, for the CAR T-first strategy to be cost-effective, CAR T can only cost $57,200 more than the total cost of BsAbs therapy.  Probabilistic sensitivity analysis was performed by running 10,000 Monte-Carlo trials, which demonstrated that BsAbs-first was cost-effective in 55% of trials, while CAR T-first was cost-effective in 45% of trials.

 

 

Conclusions

 

Despite improved clinical efficacy and effectiveness with a CAR T-first strategy for R/R FL, the increased cost resulted in a BsAbs-first strategy being the cost-effective strategy at a WTP of $150,000/QALY. However, its cost-effectiveness is highly sensitive to changes in the cost of CAR T and cost of BsAb. For example, if BsAbs are used in an extended fashion (rather than the modeled fixed-duration of therapy), a CAR T first strategy is likely cost-effective. This highlights the importance of interventions to potentially reduce the cost of CAR T, or the identification of sub-populations where CAR T is most effective, to improve the cost-effectiveness of a CAR T-first strategy, and that cost needs to be considered when sequencing novel T-cell-engaging therapies.

Swetha Thiruvengadam, MD: Innate Pharma SA - Honoraria; ADC Therapeutics - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Innate Pharma SA - Consultancy (Includes expert testimony)